The Evolving Role of β-Adrenergic Receptor Blockers in Managing Hypertension

Canadian Journal of Cardiology

Volumn 28, Issue 3, 2012, Pages 334-340

  Poirier, Luc ^a   Lacourcière, Yves ^a  

^a University Laval   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LABETALOL; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; NADOLOL; NEBIVOLOL; NITRIC OXIDE; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; TRIACYLGLYCEROL; VERAPAMIL;

ACUTE HEART FAILURE; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ATRIOVENTRICULAR BLOCK; CARDIOSELECTIVITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFUSION; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TOLERABILITY; FATIGUE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INSOMNIA; INSULIN BLOOD LEVEL; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID METABOLISM; LIPOPHILICITY; META ANALYSIS (TOPIC); NIGHTMARE; PRACTICE GUIDELINE; REVIEW; SEXUAL DYSFUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR RESISTANCE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; ATENOLOL; CARDIAC OUTPUT; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 84860898882     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.04.001     Document Type: Review

References (56)

1. Rabi D.M., Daskalopoulou S.S., Padwal R.S., et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011, 27. 415-33.e1-2.
2. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
3. Mason R.P., Giles T.D., Sowers J.R. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol 2009, 54:123-128.
4. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412. MRC Working Party.
5. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol. The international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 1985, 3:379-392. The IPPPSH Collaborative Group.
6. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
7. Wilhelmsen L., Berglund G., Elmfeldt D., et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987, 5:561-572.
8. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
9. Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
10. Black H.R., Elliott W.J., Grandits G., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 2003, 289:2073-2082.
11. Aronow W.S. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010, 11:2599-2607.
12. Lindholm L.H., Carlberg B., Samuelsson O. Should â-blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 2005, 366:1545-1553.
13. Basile J.N. One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. Am J Med 2010, 123(suppl 1):S9-S15.
14. Nagatomo T., Ohnuki T., Ishiguro M., et al. β-adrenoceptors: three dimensional structures and binding sites for ligands. Jpn J Pharmacol 2001, 87:7-13.
15. Frishman W.H., Saunders E. â-adrenergic blockers. J Clin Hypertens (Greenwich) 2011, 13:649-653.
16. Arner P. The Beta-3 adrenergic receptor--a cause and cure of obesity?. N Engl J Med 1995, 333:382-383.
17. Messerli F.H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?. JAMA 1998, 279:1903-1907.
18. Manrique C., Giles T.D., Ferdinand K.C., Sowers J.R. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens 2009, 11:369-375.
19. Giles T.D. The role of vasodilating beta-blockers in patients with complicated hypertension. Am J Medicine 2010, 123:S16-S20.
20. Ram C.V.S. Beta-blockers in hypertension. Am J Cardiol 2010, 106:1819-1825.
21. Bakris G.B. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol 2009, 53:379-387.
22. Frishman W.H. Alpha-and beta-adrenergic blocking drugs. Cardiovascular Pharmacotherapeutics 2011, 57-86. Cardiotext Inc, Minneapolis, MN. 3rd Ed. W.H. Frishman, D.A. Sica (Eds.).
23. Cruickshank J.M. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 1980, 100:160-178.
24. Salpeter S.R., Ormiston T.M., Salpeter E.E., Wood-Baker R. Cardioselective beta-blockers for reversible airway disease. Cochrane Database of Syst Rev 2002, 4. CD002992.
25. Frishman W.H. Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med 1983, 308:940-944.
26. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007, 28:3012-3019.
27. Taylor A.A., Bakris G.L. The role of vasodilating B-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med 2010, I23:S21-S26.
28. Lacourcière Y., Lefebvre J., Poirier L., Archambault F., Arnott W. A double-blind crossover comparison of nebivolol and lisinopril in ambulatory hypertension. Am J Ther 1994, 1:74-80.
29. Lacourcière Y., Poirier L., Arnott W. Comparative effects of nebivolol and nifedipine on ambulatory blood pressure and plasma lipids, lipoproteins and apolipoproteins. J Clin Pharmacol 1992, 32:660-666.
30. Dessy C., Saliez J., Ghisdal P., et al. Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005, 112:1198-1205.
31. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004, 1:17-32.
32. Pasini A.F., Garbin U., Nava M.C., et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005, 23:589-596.
33. Kamp O., Sieswarda G.T., Visser C.A. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003, 92:344-348.
34. Mahmud A., Feely K. â-blockers reduced aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008, 21:663-667.
35. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 355:1955-1964. Blood Pressure Lowering Treatment Trialists' Collaboration.
36. Khan N., McAllister F. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737-1742.
37. Hypertension: Management of Hypertension in Adults in Primary Care: Pharmacological Update. NICE Clinical Guideline 34 2006, 8. National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence, London.
38. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
39. Terai M., Ohishi M., Ito N., et al. Comparison of arterial functional evaluations as a predictor of cardiovascular events in hypertensive patients: the Non-Invasive Atherosclerotic Evaluation in Hypertension (NOAH) study. Hypertens Res 2008, 31:1135-1145.
40. Chrysant S.G. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med 1998, 7:370-376.
41. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [erratum in 2003;289:178; 2004;291:2196]. JAMA 2002, 288:29-97. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
42. Lacourcière Y., Lefebvre J., Poirier L., Archambault F., Arnott W. Treatment of ambulatory hypertension with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994, 7:137-145.
43. Kasiske B.L., Ma J.Z., Kalil R.S.N., Louis T.A. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122:133-141.
44. Gorré F., Vandekerchkove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why?. Acta Cardiol 2010, 56:565-570.
45. Poirier L., Cléroux J., Nadeau A., Lacourcière Y. Comparative effects of atenolol and nebivolol on blood pressure and insulin sensitivity in hypertensive patients with glucose intolerance. J Hypertens 2001, 19:1429-1435.
46. Torp-Pedersen C., Metra M., Charlesworth A., et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007, 93:968-973.
47. Cutler J.A., Davis B.R. Thiazide-type diuretics and B-adrenergic blockers as first-line drug treatments in hypertension. Circulation 2008, 117:2691-2705.
48. Bangalore S., Parkar S., Grossman E., Messerli F.H. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007, 100:1254-1262.
49. Abuissa H., Jones P.G., Marso S.P., et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005, 46:821-826.
50. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
51. Garcia-Touza M., Sowers J.R. State of the art: evidence-based hypertension treatment in patients with diabetes. J Clin Hypertens 2012, 14:97-102.
52. Riva N., Lip G.H. Nebivolol for the treatment of heart failure. Expert Opin Investig Drugs 2011, 20:1733-1746.
53. II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13. The Cardiac Insufficiency Bisoprolol Study.
54. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000, 283:1295-1302.
55. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
56. Man in 't Veld A.J., Schalekamp M.A. Effects of 10 different beta-adrenoreceptor antagonists on hemodynamics, plasma rennin activity and plasma norepinephrine in hypertension: the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol 1983, 5(suppl 1):S30-S45.